Skip to main content
Premium Trial:

Request an Annual Quote

Humana Press Ribozymes and siRNA Protocols Manual, and Promega s psiCheck-1 and psiCheck-2

Premium

Humana Press is preparing for publication an updated version of a bench manual entitled Ribozymes and siRNA Protocols. The manual covers methods for gene inactivation in vivo and in vitro, and specifically addresses such topics as ribozymes, DNAzymes, and RNA interference.

The book also describes techniques using hairpain ribozymes, DNAzymes, hammerhead ribozymes and derivatives, group I intron ribozymes, Rnase P ribozymes, and siRNAs.

Also covered are novel methods for identifying accessible cellular mRNA sites; group I intron and RNAse P ribozymes protocols for effective design, selection, and therapeutic applications; and the latest RNAi methods for sequencing-specific gene silencing in a wide variety of organisms, said Humana.

The book is edited by Mouldy Sioud, a researcher with The Norwegian Radium Hospital, and is set to be released in March.

Details about the text can be found at http://www.humanapress.com/Product.pasp?txtCatalog=HumanaBooks&txtCategory=&txtProductID=1%2D58829%2D226%2D6&isVariant=0.


Promega recently introduced its psiCheck-1 and psiCheck-2 vectors for RNAi.

The vectors, said the company, use Renilla luciferase as a primary reporter gene, and the gene of interest is cloned into multiple cloning regions.

“Initiation of the RNAi process by synthetic siRNAs or in vivo expressed shRNAs towards a gene of interest results in cleavage and subsequent degradation of the Renilla gene-of-interest mRNA,” said Promega. “Measuring decrease in Renilla activity conveniently monitors RNAi effect.”

Details about the vectors can be found at http://www.promega.com/catalog/CatalogProducts.asp?catalog%5Fname=Promega%5FProducts&category%5Fname=psiCHECK%2D1+and+psiCHECK%2D2+Vectors&description%5Ftext=psiCHECK%26%23x2122%3B%2D1+and+psiCHECK%26%23x2122%3B%2D2+Vectors.

 

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.